Cover Image

Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma

Mitogen-activated protein kinase pathway mutations are present in >50% of patients with relapsed/refractory (R/R) multiple myeloma (MM). MEK inhibitors show limited single-agent activity in R/R MM; combination with B-cell lymphoma-2 (BCL-2) and programmed death-ligand 1 inhibition may improve eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Schjesvold, Fredrik (Author) , Paiva, Bruno (Author) , Ribrag, Vincent (Author) , Rodriguez-Otero, Paula (Author) , San-Miguel, Jesus F. (Author) , Robak, Pawel (Author) , Hansson, Markus (Author) , Onishi, Maika (Author) , Hamidi, Habib (Author) , Malhi, Vikram (Author) , Dail, Monique (Author) , Javery, Apurva (Author) , Ku, Grace (Author) , Raab, Marc-Steffen (Author)
Format: Article (Journal)
Language:English
Published: 2023
In: Clinical lymphoma, myeloma & leukemia
Year: 2023, Volume: 23, Issue: 1, Pages: e59-e70
ISSN:2152-2669
DOI:10.1016/j.clml.2022.10.006
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clml.2022.10.006
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2152265022017128
Get full text
Author Notes:Fredrik Schjesvold, Bruno Paiva, Vincent Ribrag, Paula Rodriguez-Otero, Jesus F. San-Miguel, Pawel Robak, Markus Hansson, Maika Onishi, Habib Hamidi, Vikram Malhi, Monique Dail, Apurva Javery, Grace Ku, Marc S. Raab
Description
Summary:Mitogen-activated protein kinase pathway mutations are present in >50% of patients with relapsed/refractory (R/R) multiple myeloma (MM). MEK inhibitors show limited single-agent activity in R/R MM; combination with B-cell lymphoma-2 (BCL-2) and programmed death-ligand 1 inhibition may improve efficacy. This phase Ib/II trial (NCT03312530) evaluated safety and efficacy of cobimetinib (cobi) alone and in combination with venetoclax (ven) with/without atezolizumab (atezo) in patients with R/R MM.
Item Description:Online veröffentlicht am 22. Oktober 2022, Dateiversion vom 16. Dezember 2022
Gesehen am 07.02.2023
Physical Description:Online Resource
ISSN:2152-2669
DOI:10.1016/j.clml.2022.10.006

Similar Items